The company successfully completed a Phase IIa efficacy and safety trial, significantly reducing the number of MRI lesions in patients with multiple sclerosis and has also completed toxicology studies to support a potential future Phase IIb of ATL1102 in MS patients.s: In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders.
Classification: This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions.Antisense Therapeutics announced that it is proceeding with a Phase 2b clinical trial of ATL1102, its lead candidate to treat multiple sclerosis, after the U.S. Food and Drug Administration (FDA) lifted a clinical hold it had placed on the company’s request — in the form of a trial application or IND — for this study.A partial trial restriction, however, remains in place. The FDA agreed to allow for the Phase 2b trial, but patients — intended to be a mix of 195 people with relapsing or remitting (RRMS) and secondary progressive multiple sclerosis (SPMS) — can only be given ATL1102 infusions at a low dose, 25 mg per week, and only for up to six months,
Atl1102 for DMD:
Antisense said in a“We are moving forward with all deliberate speed to advance ATL1102 through the clinic, with specific view to a blinded controlled study in the European Union which, based upon recent and ongoing guidance, may lead directly to early approval,” Mr Diamond said.“Seeing the efficacy signals of this study, conducted with a low dose in a small number of boys over a relatively short time period, is both gratifying and immensely encouraging,” William Goolsbee, Antisense’s non-executive director and chairman of the trial’s Scientific Advisory Board, said in a press release.“[O]nly a small handful of drugs have shown indications of efficacy so early in development. In the context of DMD, we now look to have a drug,” Goolsbee added.
Antisense's research director, Dr Christopher Wraight, said the company's presentation to the Perth conference would include data indicating that ATL1102, delivered as an aerosol directly into the lungs of mice, significantly reduces the infiltration of inflammatory cells called eosinophils from the bloodstream into the lung tissues affected by asthma.At this early stage, it was not clear whether the effect was due to a change in the activation state of the eosinophils, or to loss of the cells' ability to move from the bloodstream into adjacent lung tissues.The end-effect is that by restricting the entry of eosinophils, low-dose, inhaled ATL1102 significantly reduces the airway constriction caused by asthma attacks.Wraight said the company would continue pre-clinical experiments in mice, and had no plans yet to take the asthma therapy into Phase 1 human clinical trials.
——————
Itsagas: Many people still think that ATL1102. Is only for DMD....In the next 6 months we will have ATL1102 in Phase 2B trials for DMD Nd MS and in the next 12 months more activity in Asthma and Acromegaly..
This is why Itsa is calling $2
Expand
(20min delay)
